[1]CurrentPatentAssignee:GLAXOSMITHKLINEPLC-WO2009/20990,2009,A1Locationinpatent:Page/Pagecolumn360-362
[1]SolingapuramSai,KiranKumar;Prabhakaran,Jaya;Sattiraju,Anirudh;Mann,J.John;Mintz,Akiva;Kumar,J.S.Dileep[BioorganicandMedicinalChemistryLetters,2017,vol.27,#13,p.2895-2897]
Title: Comprehensive analysis of kinase inhibitor selectivity.
Journal: Nature biotechnology 20111030
Title: Anaplastic Lymphoma Kinase: role in specific tumours, and development of small molecule inhibitors for cancer therapy.
Journal: Cancer letters 20101228
Title: Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry.
Journal: Chemistry & biology 20101124
Title: The emerging pathogenic and therapeutic importance of the anaplastic lymphoma kinase gene.
Journal: European journal of cancer (Oxford, England : 1990) 20100901
Title: GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers.
Journal: Molecular cancer therapeutics 20091001
Title: Optimization of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidine IGF-1R tyrosine kinase inhibitors towards JNK selectivity.
Journal: Bioorganic & medicinal chemistry letters 20090115
Title: Sabbatini P, et al.GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers.Mol Cancer Ther. 2009 Oct;8(10):2811-20.